FTI-2148
FTI-2148 性质
| 沸点 | 730.1±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.256±0.06 g/cm3(Predicted) |
| 溶解度 | DMSO:0.0(最大浓度 mg/mL);0.0(最大浓度 mM) |
| 酸度系数(pKa) | 3.49±0.10(Predicted) |
FTI-2148 用途与合成方法
IC50: 1.4 nM (FT-1); 1.7 μM (GGT-1)
FTI-2148 (30 μM) inhibits the farnesylation of the exclusively farnesylated protein HDJ2 in all 3 RAS-transformed NIH3T3 cells.FTI-2148 is against P. falciparum PFT, Mammalian PFT and Mammalian PGGT-I with IC 50 values of 15 nM; 0.82 nM and 1700 nM, respectively. PFT:protein farnesyltransferase; PGGT-I geranylgeranyltransferase-I.
Western Blot Analysis []
| Cell Line: | KRAS HRAS, and NRAS-transformed NIH3T3 cells |
| Concentration: | 30 μM |
| Incubation Time: | |
| Result: | Inhibited the prenylation of KRAS and NRAS. |
FTI-2148 (intraperitoneal injection; 25 or 50 mpk/day with a mini-pump; started on day 15 and stopped on day 45 and restarted day 53-83) inhibits the tumor growth by 91% in human lung adenocarcinoma A-549 cells induced mouse model. FTI-2148 (subcutaneous injection; 25 mpk/day with a mini-pump; 14 days) inhibits tumor growth by 77%by the end of the 2-week treatment in Human Xenograft Nude Mouse Model.FTI-2148 (subcutaneous injection; 100 mg/kg/day; 14 days) results in breast tumor regression in a ras transgenic mouse model. FTI-2148 (subcutaneous injection; 100 mg/kg/day; 4 days) results in 85–88% inhibition of FTase with no inhibition of GGTase I enzymatic activity in breast tumors from mice in vivo settings.
| Animal Model: | Ras transgenic mouse model |
| Dosage: | 100 mg/kg/day |
| Administration: | Subcutaneous injection; 100 mg/kg/day; 14 days |
| Result: | Induced regression by 87 ± 3% of mammary carcinomas in mice. |
